Skip to content
Screener

Ginkgo Bioworks DNA Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
-$6.43M-104%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$56.16M-84.8%
TEC
Bio-TechneTECH
$46.54M+77.7%
Revvity logo
RevvityRVTY
$48.82M-77.1%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO

Other financials

Income statement

See full
Revenue$20.2M-48.5%
Gross profit$18.4M-45.4%
Operating income-$58.5M-0.7%
Net income-$46.7M+22.5%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$172.0M-31.6%
Total debt$404.1M-5.8%
Total equity$420.3M-31.4%
Total assets$990.0M-19.6%

Cash flow

See full
Operating cash flow-$44.3M-10.0%
CapEx$2.6M+6,792%
Free cash flow-$46.9M-16.4%

Valuation

See full
Market cap$520.64M-26.0%
Enterprise value$752.73M-14.6%
P/S4.7×+1.3×

Profitability

See full
Gross margin91.8%
Operating margin-259.9%+1,304pp
Net margin-260%+718pp
FCF margin-156.3%+38.7pp

Returns & leverage

See full
Return on equity-56.3%+23.1pp
Debt / equity+0.3×
Current ratio4.6×-0.8×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054298
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Weighted average common shares outstanding:62,094,35654,858,98260,835,89654,552,006
Comprehensive loss:
Net loss(46,710)(60,300)(129,297)(151,257)
Other comprehensive (loss) income:
Foreign currency translation adjustment(34)2,586(613)3,435
Unrealized (loss) gain on available-for-sale securities(210)(83)(288)24
Total other comprehensive (loss) income(244)2,503(901)3,459
Comprehensive loss$(46,954)$(57,797)$(130,198)$(147,798)

Item 1. Financial Statements (Unaudited)

FAQ

What is Ginkgo Bioworks's comprehensive income (loss), net of tax, attributable to parent?
Ginkgo Bioworks (DNA) reported comprehensive income (loss), net of tax, attributable to parent of -$46.95M in Q2 2026.
How has Ginkgo Bioworks's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Ginkgo Bioworks's comprehensive income (loss), net of tax, attributable to parent increased by 18.8% year-over-year, from -$57.8M to -$46.95M.
What is the long-term trend for Ginkgo Bioworks's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Ginkgo Bioworks's comprehensive income (loss), net of tax, attributable to parent has grown at a -36.0% compound annual growth rate (CAGR), from -$1.84B to -$309.11M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, including both net income and other comprehensive income items like foreign currency translation and unrealized gains on securities. It provides a broader view of financial performance than net income alone by capturing volatility that bypasses the traditional income statement. Investors use this to assess the total economic impact of all financial activities on shareholder equity.

Ask your AI about Ginkgo Bioworks's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude